Lysosomal Cholesterol Efflux Drives Sustained OSK-Induced Epigenetic Rejuvenation
Hypothesis
Transient OSK expression lowers epigenetic age by activating TET enzymes, but the effect fades when doxycycline is withdrawn because methylation re‑accumulates. We propose that the durability of OSK‑mediated demethylation depends on a lysosomal‑to‑nucleus cholesterol‑efflux axis that supplies oxysterol ligands for LXRα, which in turn sustains TET activity and blocks re‑methylation. When OSK cycling stops, lysosomal cholesterol export declines, LXRα signaling wanes, and TET‑driven hydroxylation of 5‑mC drops, allowing DNMTs to restore age‑associated methylation patterns.
Mechanistic rationale
- OSK induces lysosomal biogenesis – partial reprogramming upregulates TFEB and lysosomal genes, enhancing autophagic flux (see autophagy‑TET link) [1].
- Lysosomal cholesterol export via NPC1 provides free cholesterol to the cytosol, where it is oxidized to oxysterols (24‑S‑HC, 27‑HC) [2 ]
- Oxysterols activate LXRα, a nuclear receptor that recruits co‑activators with histone‑acetyltransferase activity and can directly bind TET2 promoters, boosting their transcription [3]
- Sustained LXRα‑TET signaling maintains 5‑hmC levels at pluripotency and aging‑related loci, counteracting DNMT1/3A activity.
- Upon OSK withdrawal, lysosomal activity returns to baseline, NPC1‑mediated export falls, oxysterol levels drop, LXRα signaling declines, and TET activity wanes, permitting methylation rebound.
Testable predictions
- Prediction 1: Pharmacological inhibition of NPC1 (with U18666A) or genetic knockdown of NPC1 in mice receiving cyclic OSK will abolish the lifespan extension and prevent the drop in epigenetic age, despite normal OSK induction.
- Prediction 2: Activating LXRα with a synthetic agonist (GW3965) during the off‑doxycycline weeks will prolong the reduction in DNA methylation age and extend median survival beyond that seen with OSK alone.
- Prediction 3: Measuring lysosomal cholesterol content and oxysterol levels in liver and heart will show an inverse correlation with epigenetic age across OSK cycles; peaks of oxysterols will coincide with troughs in methylation age.
- Prediction 4: Chromatin immunoprecipitation for LXRα at the TET2 promoter will increase during OSK on‑phases and return to baseline during off‑phases; this rhythm will be lost in NPC1‑deficient cells.
Experimental approach
- Use aged wild‑type mice treated with doxycycline‑inducible OSK (weekly 2‑day on/5‑day off). Four groups: (i) OSK + vehicle, (ii) OSK + NPC1 inhibitor, (iii) OSK + LXRα agonist, (iv) OSK + both inhibitor and agonist.
- Monitor median remaining lifespan, perform epigenetic clock assays (Horvath mouse clock) on liver and heart at 4‑week intervals.
- Quantify lysosomal cholesterol (filipin staining), oxysterols (LC‑MS), LXRα target gene expression (ABCA1, SREBP1c), and TET2 occupancy (ChIP‑qPCR).
If NPC1 blockade erases OSK benefits while LXRα activation sustains them, the hypothesis gains support. Conversely, if lysosomal cholesterol export is dispensable for the epigenetic effects, the model is falsified.
Broader implications
Linking lysosomal lipid metabolism to epigenetic rejuvenation offers a mechanistic explanation for why partial reprogramming requires cyclic dosing and suggests combinatorial strategies—lysosomal enhancers or LXRα agonists—to achieve lasting rejuvenation without continuous Yamanaka factor expression.
[1] https://www.liebertpub.com/doi/10.1089/cell.2023.0072 [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC2981432/ [3] https://www.liebertpub.com/doi/10.1089/cell.2023.0072